Abbr. Expansion Instances Papers News
EHR electronic health records
BACKGROUND Missing data are common in studies using electronic health records (EHRs)-derived data.
8 7 1
LVEF left ventricular ejection fraction
BACKGROUND Statins taken for cardiovascular indications by patients with breast cancer and lymphoma during doxorubicin treatment may attenuate left ventricular ejection fraction (LVEF) decline, but the effect of statins on LVEF among patients with no cardiovascular indications is unknown.
6 6 0
TAAs tumor-associated antigens
In two murine tumor models, hematopoietic CD19+-A20 lymphoma and CD19+-B16 melanoma, mice receiving vancomycin in combination with CD19-directed CAR T cell (CART-19) therapy displayed increased tumor control and tumor-associated antigens (TAAs) cross-presentation compared with CART-19 alone.
2 2 0
mEDS myopathic Ehlers-Danlos syndrome
Mutations in the collagen XII gene cause myopathic Ehlers-Danlos syndrome (mEDS), an early-onset disease characterized by overlapping connective tissue abnormalities and muscle weakness.
1 1 0
UPCI Usual Provider Care Index
We calculated continuity of care using Continuity of Care Index (COCI) and Usual Provider Care Index (UPCI), for all visits, oncology visits, and primary care visits in acute survivorship phase.
1 1 0
COCI Continuity of Care Index
We calculated continuity of care using Continuity of Care Index (COCI) and Usual Provider Care Index (UPCI), for all visits, oncology visits, and primary care visits in acute survivorship phase.
1 1 0
PRN pro re nata
Purpose To apply machine learning models for predicting the number of pro re nata (PRN) injections of antivascular endothelial growth factor (anti-VEGF) for neovascular age-related macular degeneration (nAMD) in two years in the Comparison of AMD (age-related macular degeneration) Treatments Trials.
1 1 0
DB double-blind
METHODS Patients received placebo or teriflunomide (14 mg adult equivalent) for up to 96 weeks in the double-blind (DB) period.
1 1 0
OLE open-label extension
In the open-label extension (OLE), all patients received teriflunomide until up to 192 weeks after randomization.
1 1 0
RMS relapsing multiple sclerosis
BACKGROUND The phase 3 TERIKIDS study demonstrated efficacy and manageable safety for teriflunomide versus placebo in children with relapsing multiple sclerosis (RMS).
1 1 0